8 studies found for:    "Hemispherx Biopharma" [Exact]
Show Display Options
Rank Status Study
1 Completed The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome;   Myalgic Encephalomyelitis
Intervention: Drug: Ampligen
2 Completed The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
Conditions: HIV Seropositivity;   HIV Infection
Intervention: Drug: poly I-poly C12U
3 Completed Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers
Condition: Severe Acute Respiratory Syndrome
Intervention: Drug: Alferon LDO
4 Terminated A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
Condition: HIV Infections
Intervention: Drug: Alferon LDO
5 Terminated Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
Conditions: HIV Seropositivity;   HIV Infection
Intervention: Drug: poly I-poly C12U
6 Recruiting Safety Study of FluMist With and Without Ampligen
Condition: Influenza, Human
Interventions: Drug: FluMist + Poly I:Poly C12U 50 ug;   Drug: FluMist + Poly I:Poly C12U 200 ug;   Drug: FluMist + Poly I:Poly C12U 500 ug;   Drug: FluMist + Poly I:Poly C12U 1250 ug;   Drug: FluMist + Placebo
7 Recruiting Study of Ampligen in Chronic Fatigue Syndrome
Condition: Chronic Fatigue Syndrome
Intervention: Drug: Poly I: Poly C12U
8 Recruiting Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Procedure: Surgical resection of recurrent colorectal cancer;   Drug: Chemokine-modulatory (CKM) regimen

Indicates status has not been verified in more than two years